Neurology Central

US FDA warns of stroke risk with multiple sclerosis drug: industry news round-up

In this week’s industry news round-up we cover the latest headlines on the clearance of gammaCore™ for cluster headache, warnings of stroke risk with a multiple sclerosis drug and an investigational gene therapy for spinal muscular atrophy. Find out more about our selection of the highlights below.
Our selection of the highlights includes:

gammaCore™ receives clearance for the preventive treatment of cluster headache

electroCore (NJ, USA) has announced that it has received clearance from the US FDA for an expanded label for gammaCore™ therapy, a non-invasive vagus nerve stimulator (nVNS), for the adjunctive use for the preventive treatment of cluster headache in adult patients.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.